Standard BioTools IncLAB
Price$0.73Intrinsic value$1.81147% above price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $84.6M-7.0% YoYTTM through 30 Jun 2026
Net Income $84.9MTTM through 30 Jun 2026
Free Cash Flow -$82.6MTTM through 30 Jun 2026

Margins

Current
Gross Margin53.5%
EBITDA Margin-106.4%
Operating Margin-59.2%
Net Margin100.4%

Returns

22.7%ROE
19.9%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio5.55x
Net Debt-$455.2Mnet cash position
Cash & Equivalents$270M

Quality Metrics

Altman Z-Score-0.05
Piotroski F-Score3 / 9
FCF Margin-97.6%
Earnings-Beat Rate75.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $85.3M
Diluted EPS$0.22TTM
'19'20'21'22'23'24'25
FY2025: $-0.20

Dividend

No dividend

Capital Allocation

R&D Spend$18.4M
Capex Intensity2.7%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.